BIAF
bioAffinity Technologies, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$9.43
+7.77%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$10.50
From 52W high−88.12%
Volume10.24M
Market cap$5.66M
P/E (TTM)—
P/S (TTM)1.0x
Div yield—
Key dataSep 18, 2026
Open
$10.50
From 52W high
−88.12%
Volume
10.24M
Market cap
$5.66M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
54.9
MomentumView details →
1D Return
+7.77%
YTD Return
−42.97%
SummaryUpdated Jun 1, 2026
bioAffinity Technologies, Inc. (NASDAQ:BIAF) is a biotechnology company founded in 2014 and based in San Antonio, Texas. The company went public in September 2022 and specializes in developing non-invasive diagnostic tests and targeted cancer therapeutics. bioAffinity Technologies operates in the medical diagnostics and research sector, focusing primarily on early detection of lung cancer through innovative testing methods and researching targeted therapies to treat cancer at the cellular level.
Similar companies
Latest newsMore news →
bioAffinity Technologies announced that it was granted a Hong Kong patent covering the proprietary technology behind its noninvasive CyPath Lung lung cancer diagnostic.3d agobioAffinity Technologies and AvMEDICAL announced a nationwide federal healthcare distribution agreement for CyPath Lung, expanding sales reach and access to government healthcare systems.33d agobioAffinity Technologies, Inc. completed a private placement on August 12, 2026, issuing pre-funded warrants, Series A warrants, and Series B warrants, raising approximately $4 million in gross proceeds.38d ago